An interventional study of tDCS in Chronic Migraine, sponsored by Federal University of Paraíba. Completed at 1 site in Brazil. Open to female participants aged 20 Years to 45 Years. Per ClinicalTrials.gov, last updated 2019-08-28.
Sponsored by Federal University of Paraíba · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Migraine Disorders with a site in Brazil — 3 open to participants now, 4 under way, none of them phase 3. Migraine Disorders · Brazil.
Among the 25 studies in Migraine Disorders with a site in Brazil, this one is the 16th largest by enrollment of the 23 interventional ones that give a count, is the only one that started in 2017, is one of 11 with no phase, and was the 16th registered.
1,657 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.
Browse Migraine Disorders studies →3 of the 25 studies in Migraine Disorders with a site in Brazil are open now. Recruiting first, the newest first:
University of Sao Paulo · Sites in Brazil
Ages 18–48 · Women only
Libbs Farmacêutica LTDA · Sites in Brazil
Healthy volunteers
University of Sao Paulo · Sites in Brazil
Ages 18–60
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 20 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 4
First in 2006; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is below the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 60 across the 23 interventional studies, 701 across the 2 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 25 have an industry lead sponsor. The 10 most frequent:
Federal University of Paraíba is the lead sponsor of 73 studies on the registry; 6 are open to participants now.
Federal University of Paraíba has 4 studies filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
2 of the studies in Migraine Disorders with a site in Brazil that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07493434University of Sao PauloEvaluation of Pain Thresholds in Migraine Patients After Inhalation of Essential Oils: a Randomized Clinical Trial | 2027-03 |
| NCT06625060IpsenA Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults | 2027-10-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 25 studies in Migraine Disorders with a site in Brazil, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to compare the effects of transcranial direct current stimulation on the clinical and cognitive function in patients with chronic migraine.
The patients will be randomized into 1 of 3 groups: active tDCS for 15 minutes, active tDCS for 15 minutes, with an interval of 20 minutes and more 15 minutes os stimulation, sham tDCS for 15 minutes. The tDCS will be applied for 10 days over 2 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Active tDCS for 15 minutes for 10 days over 2 weeks. Intensity: 2 milliampere. Placement: anode - left DLPFC; cathode - right supraorbital region
Other: tDCS
Active tDCS for 15 minutes, interval of 20 minutes and more 15 minutes for 10 days over 2 weeks. Intensity: 2 milliampere. Placement: anode - left DLPFC; cathode - right supraorbital region
Other: tDCS
Sham tDCS for 15 minutes for 10 days over 2 weeks. The stimulation is non-active. Placement: anode - left DLPFC; cathode - right supraorbital region
Other: tDCS
Transcranial Current Stimulation equipment consists of an ammeter (measured with current intensity), a potentiometer (voltage controller between the electrodes), a generator (two 9-volt batteries) and two electrodes (anode and cathode). The direct low-amplitude currents released by the electrodes reach the cortex and modify the neuronal potentials.
Migraine Disability Assessment - MIDAS
Change in perform activities of daily living associate to migraine assessed on the Migraine Disability Assessment - MIDAS.
Time frame: "before treatment", "after treatment - up to 2 weeks " and "up to 1 month after the last day of treatment"
Headache Impact Test - HIT-6
Change in quality of life associate to migraine assessed on the Headache Impact Test-6 (HIT-6)
Time frame: "before treatment", "after treatment - up to 2 weeks " and "up to 1 month after the last day of treatment"
Wechsler Intelligence Scale Letters
Change in cognitive ability assessed on the Wechsler Adult Intelligence Scale Letters
Time frame: "before treatment", "after treatment - up to 2 weeks " and "up to 1 month after the last day of treatment"
Wechsler Intelligence Scale Numbers Test
Change in cognitive ability assessed on the Wechsler Adult Intelligence Scale Numbers Test
Time frame: "before treatment", "after treatment - up to 2 weeks " and "up to 1 month after the last day of treatment"
Hayling's Test Hayling's Test
Change in operational memory assessed on the Hayling's Test Evaluate operational memory
Time frame: "before treatment", "after treatment - up to 2 weeks " and "up to 1 month after the last day of treatment"
Trail Making Test part B
Change in executive functions assessed on the Trail Making Test part B
Time frame: "before treatment", "after treatment - up to 2 weeks " and "up to 1 month after the last day of treatment"
Salthouse Visual Patterns and Lyrics
Change in visual processing speed assessed on the Salthouse Visual Patterns and Lyrics
Time frame: "before treatment", "after treatment - up to 2 weeks " and "up to 1 month after the last day of treatment"
Nine Hole Peg Test
Change in the motor processing speed assessed on the Nine Hole Peg Test
Time frame: "before treatment", "after treatment - up to 2 weeks " and "up to 1 month after the last day of treatment"
Paced Auditory Serial Addition Task
Change in selective attention assessed on the Paced Auditory Serial Addition Task
Time frame: "before treatment", "after treatment - up to 2 weeks " and "up to 1 month after the last day of treatment"
Concentrated Attention Test
Change in selective attention assessed on the Concentrated Attention Test
Time frame: "before treatment", "after treatment - up to 2 weeks " and "up to 1 month after the last day of treatment"
Visual Attention Test (Attention Matrices)
Change in selective attention assessed on the Visual Attention Test (Attention Matrices)
Time frame: "before treatment", "after treatment - up to 2 weeks " and "up to 1 month after the last day of treatment"
Montreal Cognitive Assessment
Change in cognition assessed on the Montreal Cognitive Assessment
Time frame: "before treatment", "after treatment - up to 2 weeks " and "up to 1 month after the last day of treatment"
Side Effects Questionnaire
adverse effects assessment
Time frame: "every day for up to 2 weeks"
Ran from Aug 2017 to primary completion in Feb 2018, 5 months.
Of 309 non-industry interventional studies with no phase under Migraine Disorders, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's 5 months is below that.
Counting every sponsor, half of 358 studies reached it within 15 months; a quarter within 7 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Federal University of Paraíba